On Tuesday, Alkermes received a positive adjustment to its Relative Strength (RS) Rating, from 65 to 72.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Alkermes can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Alkermes is trying to complete a cup without handle with a 32.88 entry. See if the stock can clear the breakout price in heavy trading.
Earnings-per-share growth dropped last quarter from -8% to -16%, but the top line rose from -35% to -1%.
Alkermes holds the No. 45 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
